ticlopidine has been researched along with Hyperlipoproteinemia Type IV in 1 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
Hyperlipoproteinemia Type IV: A hypertriglyceridemia disorder, often with autosomal dominant inheritance. It is characterized by the persistent elevations of plasma TRIGLYCERIDES, endogenously synthesized and contained predominantly in VERY-LOW-DENSITY LIPOPROTEINS (pre-beta lipoproteins). In contrast, the plasma CHOLESTEROL and PHOSPHOLIPIDS usually remain within normal limits.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| del Rey Moreno, J | 1 |
| López Cortés, LF | 1 |
| Gómez Mateos, JM | 1 |
| Lozano de León, F | 1 |
1 other study available for ticlopidine and Hyperlipoproteinemia Type IV
| Article | Year |
|---|---|
[Agranulocytosis caused by ticlopidine].
Topics: Agranulocytosis; Humans; Hyperlipoproteinemia Type IV; Male; Middle Aged; Ticlopidine | 1992 |